
Friday, June 06, 2025 7:37:40 AM
So we know that there is no longer any real estate.
That in order to maintain the $17 million value to HMBL they raised the stake in WSCG to 48.6%…which leads to some interesting questions about how they value WSCG since that increase in the percentage does not offset the removal of that real estate asset.
We know that in Q1 only 758 Pref C shares were converted which is only a very small portion of the massive dilution we saw.
We know that 64.7% of HMBL HoldCo units were used to remove 6,000 shares of Pref C. Which is also interesting math since 6000 PrefC shares are worth $6 million but the 64.7% is worth around $11 million.
We know that BRU got 9.5% of the Holdco units so overall the $17 million asset has dropped by 78.2% to about $3.7 million.
And…there are still 5622 Pref C shares still in the books which at the current pps equates to over 18 Billion shares of dilution.
Not what many were expecting I suspect.
1) Do I own stock?
Answer: No. I don’t invest in penny stocks.
2) Why am I here?
Answer: I like debating things that I have a 95.7% chance of being right about.
3) Am I a paid basher?
Answer: Wait…what? You can get paid for this?
Recent HMBL News
- Form SEC STAFF ACTION - SEC Staff Action: ORDER • Edgar (US Regulatory) • 07/09/2025 03:00:05 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 06/05/2025 09:30:06 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 05/09/2025 09:31:33 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 04/30/2025 08:47:31 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 04/18/2025 08:05:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2025 08:34:05 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2025 03:30:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/18/2025 08:10:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2025 10:13:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2025 10:27:27 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 12/26/2024 09:05:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2024 07:25:49 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 12/20/2024 02:43:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2024 09:05:16 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 12/11/2024 10:21:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/03/2024 03:42:45 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/19/2024 09:00:38 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2024 11:14:27 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2024 04:10:18 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 09/11/2024 08:35:17 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 08/30/2024 08:40:44 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/19/2024 08:53:54 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/15/2024 08:16:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 08:05:13 PM
Glidelogic Corp. Announces Release of First AI-Generated Novel "The Thirteenth Proposal" • GDLG • Jul 11, 2025 12:20 PM
Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • FITY • Jul 10, 2025 8:30 AM
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB™, its New Sublingual Pre-Workout Supplement • ASBP • Jul 9, 2025 9:15 AM
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers • IBRX • Jul 9, 2025 9:00 AM
Fifty 1 Labs, Inc. Announces Bold Expansion Plan Powered by Nobel Prize Laureate Management Team, Cutting-Edge AI Healthcare Innovation and $350K Leadership Investment • FITY • Jul 8, 2025 8:30 AM
Avant Technologies and Partner, Ainnova, Launch Transformative Preventative Care Model for Chronic Patients Across Latin America • AVAI • Jul 8, 2025 8:00 AM